Uremic Serum and Ubiquitylation of Tissue Factor
Stent thrombosis is a major clinical problem associated with a high rate of mortality.1,2 The development of drug-eluting stents (DES) has significantly reduced restenosis compared with bare metal stents (BMS) due to the antiproliferative agents inhibiting vascular smooth muscle (VSMC) proliferation. However, the rate of stent thrombosis associated with DES continues to be a major concern with rates between 0.3 and 1.1% within 3 years.1 Thrombosis is likely in part due to the fact that the antiproliferative drugs also inhibit re-endothelization of the vessel. Furthermore, patients with chronic renal failure have worse outcomes after stenting and have as much as an 8 fold increase in 1-year cardiac mortality following coronary intervention.3
- Received December 7, 2012.
- Accepted December 11, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited